Xeltis Raises €50M To Advance Tissue-Regenerating Dialysis Access As CMS Opens Door To New Options

 
• By Marion Webb
  
Xeltis secured €50m to scale and market its aXess regenerative vascular access graft, a bioresorbable scaffold that transforms into a patient’s own living vessel. (Xeltis )

More from Financing

More from Business